Sekar Kathiresan

2022

In 2022, Sekar Kathiresan earned a total compensation of $7.8M as Chief Executive Officer at Verve Therapeutics, a 41% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$315,744
Option Awards$6,947,166
Salary$571,320
Other$12,488
Total$7,846,718

Kathiresan received $6.9M in option awards, accounting for 89% of the total pay in 2022.

Kathiresan also received $315.7K in non-equity incentive plan, $571.3K in salary and $12.5K in other compensation.

Rankings

In 2022, Sekar Kathiresan's compensation ranked 361st out of 5,753 executives tracked by ExecPay. In other words, Kathiresan earned more than 93.7% of executives.

ClassificationRankingPercentile
All
361
out of 5,753
94th
Division
Manufacturing
144
out of 3,133
95th
Major group
Chemicals And Allied Products
37
out of 1,419
97th
Industry group
Drugs
26
out of 1,320
98th
Industry
Pharmaceutical Preparations
18
out of 966
98th
Source: SEC filing on April 28, 2023.

Kathiresan's colleagues

We found two more compensation records of executives who worked with Sekar Kathiresan at Verve Therapeutics in 2022.

2022

Andrew Bellinger

Verve Therapeutics

Chief Scientific Officer

2022

Andrew Ashe

Verve Therapeutics

Chief Operating Officer

News

In-depth

You may also like